Kaitlin Mayne
Clinical Research Fellow
Kaitlin studied medicine at the University of Dundee, qualifying in 2016 before commencing foundation training in Glasgow. She continued clinical training in Glasgow, completing 2 years of core medical training before beginning higher specialty training in Renal & General Internal Medicine in 2020.
Kaitlin moved to Oxford in August 2021 to join the Heart and Renal Studies Group at CTSU as a Clinical Research Fellow on an “out-of-programme research” basis. She will work on the EMPA-KIDNEY trial, which is testing empagliflozin in patients with chronic kidney disease while working towards a higher degree during her time at CTSU.
Recent publications
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
-
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
-
Bioimpedance in CKD: an untapped resource?
Journal article
Mayne KJ. et al, (2022), Nephrol Dial Transplant
-
Bioimpedance Indices of Fluid Overload and Cardiorenal Outcomes in Heart Failure and Chronic Kidney Disease: a Systematic Review.
Journal article
Mayne KJ. et al, (2022), J Card Fail
-
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329